︎Endometrial carcinoma is the fourth most common malignant tumor in women where about 5% of women with endometrial carcinoma and atypical endometrial hyperplasia are younger than 40 years old. Atypical endometrial hyperplasia is a known precursor of endometrial carcinoma.
︎With delays in childbearing age, many young women diagnosed with endometrial carcinoma/atypical endometrial hyperplasia do not have children, so there is a strong desire to preserve fertility. High-dose progesterone therapy is usually used to achieve remission and preserve fertility for these women.
︎Considering the high recurrence rate of endometrial carcinoma/atypical endometrial hyperplasia, it is recommended that women should conceive as soon as achieving remission after fertility-sparing therapy.
︎After complete remission of endometrial carcinoma and atypical endometrial hyperplasia, achieving pregnancy in these women is a challenging issue. The two main ways by which these women can conceive are through assisted reproductive technology and spontaneous pregnancy.
︎Assisted reproductive technology could improve the pregnancy rate and increase the live birth rate in women with complete remission of endometrial carcinoma and atypical endometrial hyperplasia. The recurrence rate was also found to be lower in women with clinical pregnancy than that of women without pregnancy.
Source: https://www.sciencedirect.com/science/article/pii/S2667164621000257
Comments